Endometrial Cancer HUTCHMED (China) Limited (NASDAQ:HCM) to Post FY2023 Earnings of ($1.20) Per Share, Cantor Fitzgerald ForecastsBy adminJune 8, 20220 HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for HUTCHMED…
Endometrial Cancer HUTCHMED (China) Limited (NASDAQ:HCM) Receives Average Recommendation of “Hold” from BrokeragesBy adminMay 30, 20220 Shares of HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) have been given a consensus recommendation of “Hold” by the six…
